A series of novel imaging agents could light up tumors as they begin to form -- before they turn deadly -- and signal their transition to aggressive cancers. The compounds -- fluorescent inhibitors of the enzyme cyclooxygenase-2 (COX-2) -- could have broad applications for detecting tumors earlier, monitoring a tumor's transition from pre-malignancy to more aggressive growth, and defining tumor margins during surgical removal.